The treatment options for chronic myeloid leukemia (CML) vary based on the disease phase—chronic, accelerated, or blast—along with factors like age, overall health, and the availability of a suitable stem cell donor. Here’s a breakdown of the standard treatments for each phase:
Chronic Phase
1. Tyrosine Kinase Inhibitors (TKIs):
- The primary treatment for chronic phase CML involves the use of tyrosine kinase inhibitors (TKIs). These drugs specifically target the BCR-ABL protein, which is responsible for the uncontrolled growth of leukemia cells in CML.
- In cases where the initial TKI fails to work effectively or becomes less effective over time, a higher dose may be administered, or a different TKI may be prescribed.
- If a person experiences significant side effects from the first TKI, switching to another TKI is a viable alternative.
- In scenarios where the leukemia cells develop the T315I mutation, a more potent TKI may be considered as a treatment option.
2. Stem Cell Transplant (SCT):
- Though less common in the chronic phase, some patients may undergo an allogeneic stem cell transplant (SCT). This involves replacing the patient’s diseased bone marrow with healthy stem cells from a compatible donor. This option is typically reserved for specific cases, such as when other treatments have failed, or when the disease progresses to a more advanced stage.
Accelerated and Blast Phases
The treatment approach becomes more aggressive in the accelerated and blast phases, often involving combinations of TKIs, chemotherapy, and potentially a stem cell transplant. The goal is to regain control over the disease and return it to the chronic phase if possible.
It’s important to discuss these options with your healthcare provider to determine the most appropriate treatment plan based on your specific condition.
